Kyverna Therapeutics (NASDAQ:KYTX) Given New $6.00 Price Target at HC Wainwright

Kyverna Therapeutics (NASDAQ:KYTX) had its target price lowered by HC Wainwright from $7.00 to $6.00 in a research report released on Wednesday morning,Benzinga reports. The firm currently has a neutral rating on the stock.

A number of other brokerages also recently issued reports on KYTX. UBS Group assumed coverage on Kyverna Therapeutics in a report on Thursday, October 10th. They set a “buy” rating and a $13.00 price target on the stock. Rodman & Renshaw started coverage on Kyverna Therapeutics in a research note on Wednesday, October 9th. They issued a “buy” rating and a $16.00 price target on the stock. Wells Fargo & Company reduced their price objective on Kyverna Therapeutics from $44.00 to $24.00 and set an “overweight” rating for the company in a research report on Friday, November 15th. JPMorgan Chase & Co. lowered their target price on Kyverna Therapeutics from $39.00 to $33.00 and set an “overweight” rating on the stock in a report on Wednesday, July 31st. Finally, RODMAN&RENSHAW upgraded Kyverna Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 9th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Kyverna Therapeutics presently has an average rating of “Buy” and a consensus price target of $25.71.

Kyverna Therapeutics Trading Up 1.0 %

KYTX opened at $4.12 on Wednesday. Kyverna Therapeutics has a 12 month low of $3.94 and a 12 month high of $35.06. The business’s 50-day moving average price is $5.34 and its 200-day moving average price is $8.26.

Kyverna Therapeutics (NASDAQ:KYTX) last announced its earnings results on Wednesday, November 13th. The company reported ($0.80) EPS for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.01. The business had revenue of $0.01 million for the quarter. On average, equities analysts forecast that Kyverna Therapeutics will post -3.31 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Kyverna Therapeutics

Several institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. purchased a new position in shares of Kyverna Therapeutics in the first quarter worth $6,563,000. Avoro Capital Advisors LLC purchased a new position in Kyverna Therapeutics in the 1st quarter worth $11,799,000. Price T Rowe Associates Inc. MD acquired a new stake in Kyverna Therapeutics during the 1st quarter worth about $23,093,000. Blackstone Inc. purchased a new stake in Kyverna Therapeutics during the 1st quarter valued at about $2,484,000. Finally, Bain Capital Life Sciences Investors LLC purchased a new stake in Kyverna Therapeutics in the first quarter valued at approximately $78,590,000. 18.08% of the stock is currently owned by institutional investors and hedge funds.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.